Nat. Rev. Rheumatol. doi: /nrrheum

Slides:

Advertisements

Similar presentations

NATIONWIDE PREVALENCE OF RA AND PENETRATION OF DMARDS IN SWEDEN Neovius M, Simard J & Askling J for the ARTIS Study Group Clinical Epidemiology Unit and.

Advertisements

NSAIDs and Radiographic Progression in Ankylosing Spondylitis By Abd El-Samad El-Hewala Professor of Rheumatology and Rehabilitation Faculty of Medicine.

XVI Congreso Panamericano de Reumatología Latin American biologics registries: Building on the European Experience Prof. David Cezar Titton Hospital.

Fig. 1. Drug survival curve for patients treated with a fully human anti‐TNF moAb (D2E7; n=61) or MTX (n=137). Percentage of patients still on therapy.

From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness.

Rheumatoid arthritis The Lancet

My Treatment Approach to Rheumatoid Arthritis

Recommendations for the treatment of established RA (disease duration 6 month or longer). Biologic, biological originator DMARD or boDMARD; DMARD, disease-modifying.

Prediction of Response to Targeted Treatment in Rheumatoid Arthritis

Figure 1 Lymphocytes during the disease

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Figure 1 Historical evolution of the clinical classification and

Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Methods to detect trough levels of therapeutic antibodies

Figure 2 Assays for detecting antidrug antibodies to TNF inhibitors

My Treatment Approach to Rheumatoid Arthritis

Figure 2 Heat map of targeted therapies in autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

What Is a Biosimilar?. Biosimilar Application in RA Clinical Practice: Current Knowledge and New Data

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Figure 1 Schematic comparison of expected

Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications T.-L. Liao, Y.-M.

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Simplified EULAR and GRAPPA

Figure 2 Simplified EULAR and GRAPPA

Figure 3 Transcriptome studies performed in the target

Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Mean change from baseline in disease.

Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 1 Location of HLA variants known to be associated

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

Figure 3 Strategies to achieve therapeutic inhibition of IL-1

Advancing the Treatment of IBD With Biologics

Figure 2 Overlap of associated loci among five rheumatic diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Work arrangements, productivity, and self-confidence at work as affected by RA. a For example: Stopped working altogether, moved from full-time to part-time.

EULAR Study Group on Registers and Observational Drug Studies (RODS)

Figure 3 Statistical approaches for the analysis of metabolomic data

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Multi-hit model for autoimmune diseases

Association between anti-CCP antibody status and response to remission, LDA and mACR by anti-CCP status and TNFi initiators (multivariable models). Association.

Figure 1 Simplified EULAR and GRAPPA

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Emerging hallmarks of T cells in rheumatoid arthritis

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Reproductive health in patients with rheumatic diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Mean change from baseline CDAI in abatacept and TNFi initiators with a typical patient profile. Mean change from baseline CDAI in abatacept and TNFi initiators.

Nat. Rev. Nephrol. doi: /nrneph

Mean change from baseline in disease and disability outcomes at 6 months for TNFi initiators by anti-CCP status. Mean change from baseline in disease and.

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Cardiol. doi: /nrcardio

Abatacept drug retention according to gross domestic product (GDP) groups (Crude Cox regression). Abatacept drug retention according to gross domestic.

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Nat. Rev. Rheumatol. doi: /nrrheum

Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.

Figure 1 The role of macrophages in RA

Step-down efficacy through week 48: categorical CDAI state DMARD-IR (RA-BEAM, RA-BUILD, RA-BEACON) analysis set. Step-down efficacy through week 48: categorical.

Efficacy in patients who received biologic and nonbiologic disease-modifying antirheumatic drugs in combination with rituximab. aLast-observation carried-forward.

Improvement in FACIT-F fatigue score according to ACR20 response status (ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic.

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

All registries/studies are anti-TNF focused, excepting ORA (abatacept), AIR (rituximab), and RABBIT (anti-TNFs and anakinra). AIR = Autoimmunity and Rituximab;

Incidence rates of hospitalised infection per 100 person-years, standardised for age and sex, among patients with RA from five RA registries and one RA.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Suggested therapeutic management according to subtypes and severity of rheumatic immune-related adverse events (irAE). *Add-on therapy with DMARDs (disease-modifying.

Presentation transcript:

Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.81 Figure 1 Timeline showing the founding of European biologics registers for rheumatoid arthritis Figure 1 | Timeline showing the founding of European biologics registers for rheumatoid arthritis. Registers are listed alphabetically. AIR, Autoimmunity and Rituximab; ARTIS, Antirheumatic Therapies in Sweden; ATTRA, Czech National Registry of Patients Treated with Anti-TNF Drugs; BIOBADASER, Base de Datos de Productos Biológicos de la Sociedad Española de Reumatología; BIOROSS, Russian National Biologic Registry; BioRx, Slovenian National Biologic Registry; BSRBR, British Society for Rheumatology Biologics Register; DANBIO, Danish National Registry for Biologic Therapy; DREAM, Dutch Rheumatoid Arthritis Monitoring Registry; ERSBR, Estonian Society for Rheumatology Biologics Register; GISEA, Grupo Italiano di Studio Sulla Early Arthritis; HeRBT, Hellenic Registry for Biologic Therapies; HU‑REGA, Hungarian National Biologic Registry; HÜR-BIO, Hacettepe University Rheumatology Biologic Registry; ICEBIO, Iceland National Biologics Registry; LORHEN, Lombardy Rheumatology Network; MIRA, MabThera in Rheumatoid Arthritis; NARRAS, National Registry of Patients with Rheumatoid Arthritis; NOR-DMARD, Norwegian Disease-Modifying Antirheumatic Drug Registry; ORA, Orencia in Rheumatoid Arthritis; RABBIT, Rheumatoid Arthritis Observation of Biologic Therapy; RATIO, Research Axed on Tolerance of Biotherapies; REGATE, Longitudinal Study on Patients with Rheumatoid Arthritis and Study on Tolerance and Efficacy of Tocilizumab (also known as REGistry- RoAcTEmra); Reuma.pt, The Rheumatic Diseases Portuguese Register; ROB-FIN, National Register of Biologic Treatment in Finland; SCQM‑RA, Swiss Clinical Quality Management Programme for Rheumatoid Arthritis. Nikiphorou, E. et al. (2017) Biologics registers in RA: methodological aspects, current role and future applications Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.81